<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444287</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0918 (JKN 0927)</org_study_id>
    <nct_id>NCT01444287</nct_id>
  </id_info>
  <brief_title>Daytime Corneal Swelling During Wear of Narafilcon B Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to measure daytime open-eye response to wearing of narafilcon
      B lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Thickness</measure>
    <time_frame>After 8 hours of contact lens wear</time_frame>
    <description>Percentage of corneal swelling (positive value) or deswelling (negative value) measured with Haag-Streit pachymetry equipment in microns, reported as a percent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Blebs</measure>
    <time_frame>baseline, after 20 minutes of treatment conditions</time_frame>
    <description>Corneal images captured with equipment are measured, manually outlined to estimate total bleb area from 0 to 100%. This is measured as a change in percentage after 20 minutes compared to the value prior to lens wear (baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limbal Redness</measure>
    <time_frame>Baseline, After 8 hours of treatment conditions</time_frame>
    <description>Scale of 0 to 4, where 0=none and 4= severe redness. Measure reported as a comparison of 8 hours of wear to baseline with the difference being reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Comfort</measure>
    <time_frame>after 8 hours</time_frame>
    <description>Patient reported subjective comfort of lenses or spectacles (range 0-100, where 100 is best).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Spectacles No Lenses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>narafilcon B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polymacon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lotrafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon B</intervention_name>
    <description>test product</description>
    <arm_group_label>narafilcon B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polymacon</intervention_name>
    <description>marketed product</description>
    <arm_group_label>polymacon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A</intervention_name>
    <description>marketed product</description>
    <arm_group_label>lotrafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spectacles</intervention_name>
    <description>None - subject used own spectacles</description>
    <arm_group_label>Spectacles No Lenses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be of legal age (i.e. â‰¥ 18 years).

          -  Be mentally competent, willing and able to sign a written informed consent form.

          -  Have contact lens distance sphere requirement in the range -1.00D to -6.00D.

          -  Have spectacle astigmatism &lt;1.25D in each eye.

          -  Currently wear soft contact lenses (for at least 6 months prior to the trial) with
             documentation of current prescription.

          -  Have normal eyes with no evidence of abnormality or disease. For the purpose of this
             study a normal eye is defined as one having: i) no evidence of lid abnormality or
             infection; ii) no conjunctival abnormality or infection; iii) no clinically
             significant slit lamp findings (i.e, edema, staining, scarring, vascularization,
             infiltrates or abnormal opacities); iv) no other active ocular disease.

        Exclusion Criteria:

          -  Required concurrent ocular medication.

          -  Any systemic illness which would contra-indicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Eye injury or surgery within eight weeks immediately prior to enrollment for this
             study.

          -  Abnormal lacrimal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  Pregnancy, lactating or planning a pregnancy at the time of enrollment.

          -  Participation in any concurrent clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel Brennan, McOptom PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coles-Brennan Pty Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coles-Brennan Pty Ltd</name>
      <address>
        <city>Hawthorn</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <results_first_submitted>March 27, 2014</results_first_submitted>
  <results_first_submitted_qc>April 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2014</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 22 subjects enrolled to the study, all completed the four experimental sessions.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations. The four arms were Spectacles (no contact lenses), Narafilcon B, Polymacon A, and Lotrafilcon A, in random order during the sessions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects who were enrolled and randomized to a trial arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corneal Thickness</title>
        <description>Percentage of corneal swelling (positive value) or deswelling (negative value) measured with Haag-Streit pachymetry equipment in microns, reported as a percent.</description>
        <time_frame>After 8 hours of contact lens wear</time_frame>
        <population>Subjects are those enrolled and randomized to a trial arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Spectacles No Lenses</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon B</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O3">
            <title>Polymacon</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Thickness</title>
          <description>Percentage of corneal swelling (positive value) or deswelling (negative value) measured with Haag-Streit pachymetry equipment in microns, reported as a percent.</description>
          <population>Subjects are those enrolled and randomized to a trial arm.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.15"/>
                    <measurement group_id="O2" value="-0.99" spread="0.18"/>
                    <measurement group_id="O3" value="0.75" spread="0.21"/>
                    <measurement group_id="O4" value="-1.02" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: No Lenses (control) - narafilcon B (test) = 0. Ha: No Lenses (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.636</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2093</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ho: Polymacon (+ control) - Narafilcon B (test) = 0. Ha: Polymacon (+ control) - Narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.743</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2093</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control - Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ho: lotrafilcon A (control) - narafilcon B (test) = 0. Ha: lotrafilcon A (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8957</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0275</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2093</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Blebs</title>
        <description>Corneal images captured with equipment are measured, manually outlined to estimate total bleb area from 0 to 100%. This is measured as a change in percentage after 20 minutes compared to the value prior to lens wear (baseline).</description>
        <time_frame>baseline, after 20 minutes of treatment conditions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectacles No Lenses</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon B</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O3">
            <title>Polymacon</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Blebs</title>
          <description>Corneal images captured with equipment are measured, manually outlined to estimate total bleb area from 0 to 100%. This is measured as a change in percentage after 20 minutes compared to the value prior to lens wear (baseline).</description>
          <units>percentage of bleb area</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.31"/>
                    <measurement group_id="O2" value="0.49" spread="0.23"/>
                    <measurement group_id="O3" value="0.41" spread="0.40"/>
                    <measurement group_id="O4" value="0.38" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: No Lenses (control) - narafilcon B (test) = 0. Ha: No Lenses (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0692</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0031</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ho: Polymacon (+ control) - Narafilcon B (test) = 0. Ha: Polymacon (+ control) - Narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7301</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0032</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ho: lotrafilcon A (control) - narafilcon B (test) = 0. Ha: lotrafilcon A (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8055</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0032</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Limbal Redness</title>
        <description>Scale of 0 to 4, where 0=none and 4= severe redness. Measure reported as a comparison of 8 hours of wear to baseline with the difference being reported.</description>
        <time_frame>Baseline, After 8 hours of treatment conditions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectacles No Lenses (Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon B (Test)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O3">
            <title>Polymacon (+ Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A (Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Limbal Redness</title>
          <description>Scale of 0 to 4, where 0=none and 4= severe redness. Measure reported as a comparison of 8 hours of wear to baseline with the difference being reported.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.06"/>
                    <measurement group_id="O2" value="-0.04" spread="0.5"/>
                    <measurement group_id="O3" value="0.64" spread="0.10"/>
                    <measurement group_id="O4" value="0.13" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: No Lenses (control) - narafilcon B (test) = 0. Ha: No Lenses (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9127</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1111</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ho: Polymacon (+ control) - Narafilcon B (test) = 0. Ha: Polymacon (+ control) - Narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6864</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1098</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ho: lotrafilcon A (control) - narafilcon B (test) = 0. Ha: lotrafilcon A (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1256</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1705</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1098</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Comfort</title>
        <description>Patient reported subjective comfort of lenses or spectacles (range 0-100, where 100 is best).</description>
        <time_frame>after 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spectacles No Lenses (Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon B (Test)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O3">
            <title>Polymacon (+ Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
          <group group_id="O4">
            <title>Lotrafilcon A (Control)</title>
            <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort</title>
          <description>Patient reported subjective comfort of lenses or spectacles (range 0-100, where 100 is best).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" spread="1.3"/>
                    <measurement group_id="O2" value="96.1" spread="1.0"/>
                    <measurement group_id="O3" value="78.3" spread="5.1"/>
                    <measurement group_id="O4" value="80.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: No Lenses (control) - narafilcon B (test) = 0. Ha: No Lenses (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9892</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0688</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ho: Polymacon (+ control) - Narafilcon B (test) = 0. Ha: Polymacon (+ control) - Narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.984</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ho: lotrafilcon A (control) - narafilcon B (test) = 0. Ha: lotrafilcon A (control) - narafilcon B (test) â‰  0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.984</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The mean difference is calculated as: Control-Test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Spectacles No Lenses</title>
          <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
        </group>
        <group group_id="E2">
          <title>Narafilcon B</title>
          <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
        </group>
        <group group_id="E3">
          <title>Polymacon A</title>
          <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
        </group>
        <group group_id="E4">
          <title>Lotrafilcon A</title>
          <description>Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Noel Brennan</name_or_title>
      <organization>Vistakon</organization>
      <phone>1 904 4433494</phone>
      <email>nbrenna2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

